association between variant y402h in age-related macular degeneration (amd) susceptibility gene cfh and treatment response of amd a meta-analysis关联变异y402h在年龄相关性黄斑变性(amd)易感性基因cfh amd的荟萃分析和治疗反应.pdf

Association between Variant Y402H in Age-Related Macular Degeneration (AMD) Susceptibility Gene CFH and Treatment Response of AMD: A Meta-Analysis 1 2 1 Han Chen *, Ke-Da Yu *, Ge-Zhi Xu * 1 Department of Ophthalmology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, People’s Republic of China, 2 Shanghai Cancer Center and Cancer Institute, Fudan University, Shanghai, People’s Republic of China Abstract Purpose: To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD. Methods: We performed a literature-based meta-analysis including 10 published association studies involving 1,510 patients. Treatments included anti-VEGF (bevacizumab and ranibizumab) or photodynamic therapy. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Q-statistic test was used to assess heterogeneity. Results: Polymorphism rs1061170 showed a significant summary OR of 1.68 (95% CI, 1.09 to 2.60; P = 0.020; CC versus TT; random-effects) for treatment response of neovascular AMD with heterogeneity of 0.09. In subgroup analysis, rs1061170 was more likely to be a predictor of response to anti-VEGF therapy (P = 0.011). However, heterozygous TC genotype was not associated with altered treatment response (OR = 1.18, 95% CI, 0.95 to 1.47; P = 0.145; fixed-effects). Influence analysis indicated the robustness of our findings. Conclusions: rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. It might be the first meta-analytically confirmed genetic marker predictive for A